-
Something wrong with this record ?
CC and CXC chemokines patterns in psoriasis determined by protein array method were influenced by Goeckerman's therapy
David Pohl, Ctirad Andrýs, Lenka Borská, Zdeněk Fiala, Květa Hamáková, Karel Ettler, Jan Krejsek
Language English Country Czech Republic
Digital library NLK
Full text - Article
Issue
Volume
Source
Source
NLK
Directory of Open Access Journals
from 1997
Free Medical Journals
from 1997
Open Access Digital Library
from 1997-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1997
- MeSH
- Chemokines, CC blood MeSH
- Chemokines, CXC blood MeSH
- Protein Array Analysis MeSH
- Coal Tar administration & dosage MeSH
- Child MeSH
- Financing, Organized MeSH
- Keratolytic Agents administration & dosage MeSH
- Humans MeSH
- Adolescent MeSH
- Psoriasis blood therapy MeSH
- Ultraviolet Therapy MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
Goeckerman's therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. The aim of this study was to evaluate the influence of Goeckerman's therapy of psoriasis on the levels of proangiogenic chemokines ENA-78 (CXCL5, Epithelial Cell Derived Neutrophil Attractant- 78), GRO alpha (CXCL1, Growth-Related Oncogene), IL-8 (CXCL8, Interleukin-8), MCP-1 (CCL2, Monocyte Chemotactic (Chemoattractant) Protein 1) and RANTES (CCL5, Regulated on Activation of Normal T Cell Expressed and Secreted) in peripheral blood of 22 children's patients with psoriasis. 22 otherwise healthy children serve as a control group. The serum levels of chemokines were determined by commercial membrane protein array technique (RayBiotech, USA). Efficacy of Goeckerman's therapy was delineated by PASI score. Disease activity was significantly diminished by Goeckerman's therapy (p<0.001). Serum levels of GRO alpha and MCP-1 in patients before GT were significantly higher than those measured in healthy blood donors (GRO alpha: p=0.0128 and MCP-1: p=0.0003). Serum levels of GRO alpha, MCP-1 and RANTES were significantly diminished by GT (GRO alpha: p=0.002, MCP-1: p=0.048 and RANTES: p=0.0131). Compared to the healthy controls, serum level of MCP-1 remained significantly increased in psoriasis patients after GT (p<0.0001). In conclusion, we found that the GT of psoriasis influenced the serum levels of proinflammatory and proangiogenic chemokines, especially GRO alpha, MCP-1 and RANTES. It could be the cause for decreased proangiogenic activity which is described after GT of psoriasis.
References provided by Crossref.org
Lit.: 31
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07528409
- 003
- CZ-PrNML
- 005
- 20111210145404.0
- 008
- 090907s2009 xr e eng||
- 009
- AR
- 024 7_
- $a 10.14712/18059694.2016.100 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Pohl, David $7 xx0104099
- 245 10
- $a CC and CXC chemokines patterns in psoriasis determined by protein array method were influenced by Goeckerman's therapy / $c David Pohl, Ctirad Andrýs, Lenka Borská, Zdeněk Fiala, Květa Hamáková, Karel Ettler, Jan Krejsek
- 314 __
- $a Charles University in Prague, Faculty of Medicine and University Hospital, Hradec Králové
- 504 __
- $a Lit.: 31
- 520 9_
- $a Goeckerman's therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. The aim of this study was to evaluate the influence of Goeckerman's therapy of psoriasis on the levels of proangiogenic chemokines ENA-78 (CXCL5, Epithelial Cell Derived Neutrophil Attractant- 78), GRO alpha (CXCL1, Growth-Related Oncogene), IL-8 (CXCL8, Interleukin-8), MCP-1 (CCL2, Monocyte Chemotactic (Chemoattractant) Protein 1) and RANTES (CCL5, Regulated on Activation of Normal T Cell Expressed and Secreted) in peripheral blood of 22 children's patients with psoriasis. 22 otherwise healthy children serve as a control group. The serum levels of chemokines were determined by commercial membrane protein array technique (RayBiotech, USA). Efficacy of Goeckerman's therapy was delineated by PASI score. Disease activity was significantly diminished by Goeckerman's therapy (p<0.001). Serum levels of GRO alpha and MCP-1 in patients before GT were significantly higher than those measured in healthy blood donors (GRO alpha: p=0.0128 and MCP-1: p=0.0003). Serum levels of GRO alpha, MCP-1 and RANTES were significantly diminished by GT (GRO alpha: p=0.002, MCP-1: p=0.048 and RANTES: p=0.0131). Compared to the healthy controls, serum level of MCP-1 remained significantly increased in psoriasis patients after GT (p<0.0001). In conclusion, we found that the GT of psoriasis influenced the serum levels of proinflammatory and proangiogenic chemokines, especially GRO alpha, MCP-1 and RANTES. It could be the cause for decreased proangiogenic activity which is described after GT of psoriasis.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a chemokiny CC $x krev $7 D019742
- 650 _2
- $a chemokiny CXC $x krev $7 D019743
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a dehet uhelný $x aplikace a dávkování $7 D003033
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a keratolytika $x aplikace a dávkování $7 D007641
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a čipová analýza proteinů $7 D040081
- 650 _2
- $a psoriáza $x krev $x terapie $7 D011565
- 650 _2
- $a terapie ultrafialovými paprsky $7 D014467
- 700 1_
- $a Andrýs, Ctirad, $d 1962- $7 mzk2008430528
- 700 1_
- $a Borská, Lenka $7 nlk20060173900
- 700 1_
- $a Fiala, Zdeněk, $d 1955- $7 nlk19990073147
- 700 1_
- $a Hamáková, Květoslava $7 xx0064204
- 700 1_
- $a Ettler, Karel, $d 1957- $7 nlk19990073134
- 700 1_
- $a Krejsek, Jan, $d 1958- $7 nlk19990073429
- 773 0_
- $w MED00010947 $t Acta medica (Hradec Králové) $g Roč. 52, č. 1 (2009), s. 9-13 $x 1211-4286
- 856 41
- $u https://actamedica.lfhk.cuni.cz/media/pdf/am_2009052010009.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 3077 $c 1072 $y 8
- 990 __
- $a 20090907111624 $b ABA008
- 991 __
- $a 20111108144938 $b ABA008
- 999 __
- $a ok $b bmc $g 678953 $s 538911
- BAS __
- $a 3
- BMC __
- $a 2009 $b 52 $c 1 $d 9-13 $i 1211-4286 $m Acta Medica $x MED00010947
- LZP __
- $a 2009-30/mkme